We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Tells Aastrom to Hold Clinical Trial After SAE Reported
FDA Tells Aastrom to Hold Clinical Trial After SAE Reported
February 6, 2009
The FDA told Aastrom Biosciences to place on clinical hold its Phase II trial of a treatment to repair heart muscle in patients with heart failure after a patient suffered a serious adverse event (SAE) related to anesthesia management.